PORTEC-3 Trial: Adjuvant Chemoradiotherapy for High-Risk Endometrial Cancer
The PORTEC-3 trial studied combined chemoradiotherapy (cisplatin 50 mg/m² on days 1 and 29 during pelvic external beam radiotherapy [48.6 Gy], followed by 4 cycles of carboplatin AUC 5 plus paclitaxel 175 mg/m² every 3 weeks) versus radiotherapy alone in 686 patients with high-risk endometrial cancer, demonstrating improved 5-year overall survival (81.4% vs 76.1%, HR 0.70, p=0.034) and failure-free survival (76.5% vs 69.1%, HR 0.70, p=0.016), with the greatest benefit seen in stage III disease and serous histology. 1, 2, 3
Trial Design and Patient Population
The PORTEC-3 trial enrolled women with high-risk endometrial cancer defined as:
- Stage I, grade 3 with deep myometrial invasion AND lymphovascular space invasion (LVSI)
- Stage II (any grade)
- Stage III (any grade, endometrioid histology)
- Stage I-III serous or clear cell carcinoma 1, 2
This represented approximately 15% of all endometrial cancer patients, with about half having high-risk early-stage disease and 45% having stage III disease 4, 5.
Treatment Regimen Details
Chemoradiotherapy Arm:
- Concurrent phase: Cisplatin 50 mg/m² IV on day 1 and day 29 during pelvic EBRT (48.6 Gy in 1.8 Gy fractions, 5 days/week)
- Adjuvant phase: Carboplatin AUC 5 + paclitaxel 175 mg/m² IV every 3 weeks × 4 cycles (escalated to AUC 6 in subsequent cycles as tolerated) 1, 4, 2
Radiotherapy Alone Arm:
Efficacy Outcomes
At median follow-up of 72.6 months 3:
Overall Survival:
- 5-year OS: 81.4% (chemoradiotherapy) vs 76.1% (radiotherapy alone)
- Hazard ratio: 0.70 (95% CI 0.51-0.97, p=0.034) 1, 3
Failure-Free Survival:
- 5-year FFS: 76.5% (chemoradiotherapy) vs 69.1% (radiotherapy alone)
- Hazard ratio: 0.70 (95% CI 0.52-0.94, p=0.016) 1, 3
Recurrence Patterns:
Distant metastases were the predominant site of first recurrence, occurring in 21.4% with chemoradiotherapy versus 29.1% with radiotherapy alone (HR 0.74, p=0.047). Isolated vaginal recurrence was rare (0.3% in both groups), and isolated pelvic recurrence occurred in only 0.9% of patients in each arm 3.
Subgroup Analysis: Who Benefits Most?
Patients with stage III disease and serous histology derived the greatest benefit from combined therapy 1. For stage I-II non-serous cancers, the absolute improvement was modest (2% in 5-year OS, 4% in FFS), making the decision for combined treatment more nuanced in this subgroup 6.
Molecular Subtype Analysis:
A critical follow-up molecular analysis stratified outcomes by molecular classification 1:
- p53 abnormal: 5-year RFS 59% (chemoradiotherapy) vs 36% (radiotherapy) - substantial benefit
- POLE mutated: 100% vs 97% - excellent outcomes regardless
- MMR-deficient: 68% vs 76% - no benefit, possibly worse with chemotherapy
- No specific molecular profile: 80% vs 68% - moderate benefit
This molecular data suggests systemic therapy is most beneficial for p53 abnormal tumors and should be considered carefully in MMR-deficient disease 1.
Toxicity Profile
Acute Toxicity (During Treatment):
- Grade ≥3 adverse events: 60% (chemoradiotherapy) vs 12% (radiotherapy alone), p<0.0001
- Most grade 3 events were hematological toxicity (45%) 5
- Grade ≥2 adverse events: 94% vs 44% 5
Long-Term Toxicity (5 Years):
- Grade ≥2 adverse events: 38% (chemoradiotherapy) vs 24% (radiotherapy alone), p=0.008 7
- Grade 3 adverse events: 8% vs 5%, p=0.18 (not significantly different) 7, 3
- Only one new late grade 4 toxicity (ileus/obstruction) reported at 5 years 3
Persistent Sensory Neuropathy - The Major Long-Term Issue:
Sensory neuropathy represents the most clinically significant persistent toxicity:
- At 3 years: Grade ≥2 neuropathy in 8% (chemoradiotherapy) vs 0% (radiotherapy alone), p<0.001 7
- At 5 years: Grade ≥2 neuropathy in 6% vs 0%, p<0.001 7, 3
- Patient-reported tingling/numbness at 3 years: 27% vs 8%, p<0.001 7
- Patient-reported tingling/numbness at 5 years: 24% vs 9%, p=0.002 7
This persistent neuropathy at 5 years in approximately 1 in 4 patients is a critical consideration for shared decision-making 7.
Quality of Life Impact
Early Impact (Up to 3 Years):
- Physical functioning: Lower scores (79 vs 87, p<0.001) 7
- Role functioning: Lower scores (78 vs 88, p<0.001) 7
- Limb weakness: More common (21% vs 5%, p<0.001) 7
Long-Term (3-5 Years):
- Global health/quality of life scores: Similar between groups and better than normative population 7
- Physical and role functioning impairments resolved by 3 years, except for persistent neuropathy symptoms 7, 5
Clinical Context and Competing Evidence
GOG-258 Trial Comparison:
The GOG-258 trial compared chemoradiotherapy (similar regimen) versus chemotherapy alone (carboplatin/paclitaxel × 6 cycles) in stage III-IVA disease and found no difference in recurrence-free survival (59% vs 58%) 1, 4. This creates clinical equipoise about whether radiation adds benefit when chemotherapy is given, though OS data from GOG-258 remain pending 1.
GOG-249 Trial:
In high-intermediate risk disease, GOG-249 showed that vaginal brachytherapy plus chemotherapy was not superior to pelvic radiotherapy alone, with similar 5-year RFS and OS but significantly more acute toxicity (grade ≥2 in 94% vs 44%) and persistent neuropathy (10% vs <1% at 24 months) 6.
Treatment Compliance and Feasibility
The PORTEC-3 regimen demonstrated good feasibility:
- No treatment discontinuation during chemoradiotherapy 8
- 92.7% of patients completed all 4 planned adjuvant chemotherapy cycles 8
- Similar compliance rates observed in South Asian cohorts 8
Practical Clinical Algorithm
For high-risk endometrial cancer after complete surgical staging:
Stage III disease or serous/clear cell histology: Strongly recommend combined chemoradiotherapy (PORTEC-3 regimen) - absolute benefit ~5% in OS 1, 6, 3
Stage I-II with p53 abnormal molecular profile: Recommend combined chemoradiotherapy - substantial benefit demonstrated in molecular subanalysis 1
Stage I-II with MMR-deficient profile: Consider chemotherapy alone or clinical trial with immunotherapy; avoid routine combined therapy given lack of benefit 1
Stage I-II with POLE mutation: Consider observation or de-escalated therapy given excellent prognosis 1
Stage I-II with no specific molecular profile: Individualized discussion weighing modest benefit (2-4% absolute improvement) against toxicity, particularly persistent neuropathy risk 6
Critical Counseling Points
When discussing PORTEC-3 regimen with patients, emphasize:
- Survival benefit is modest overall (5% absolute improvement in 5-year OS) but more substantial in stage III/serous histology
- 1 in 4 patients will experience persistent tingling/numbness at 5 years that impacts quality of life 7
- Most recurrences occur at distant sites within first 2 years (80% within 2 years), suggesting systemic therapy targets the primary failure pattern 8
- Physical and role functioning recover by 3 years except for neuropathy 7
- Molecular classification significantly impacts benefit - p53 abnormal tumors benefit most 1
Current Guideline Recommendations
NCCN 2023 guidelines recommend combined chemoradiotherapy for high-risk endometrial cancer based on PORTEC-3, with particular emphasis on stage III disease and serous histology 1. The ESMO 2022 guidelines similarly recommend combined therapy for high-risk disease (stage III-IVA without residual disease, or stage I-IVA p53 abnormal/non-endometrioid with myometrial invasion) 6.
The 2025 ESGO-ESTRO-ESP guidelines incorporate molecular classification, recommending external beam radiotherapy with concurrent and adjuvant chemotherapy for stage III-IVA MMR-deficient, NSMP, or p53 abnormal endometrial carcinomas, with consideration of immunotherapy for MMR-deficient disease 9.